Patents by Inventor Andrea Gramatica

Andrea Gramatica has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor
    Patent number: 11590110
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus using a glycogen synthase kinase 3? inhibitor, such as a glycogen synthase kinase 3? (GSK-3?) or a glycogen synthase kinase 3? (GSK-3?) inhibitor. In some embodiments, the glycogen synthase kinase 3 inhibitor is a glycogen synthase kinase antagonist, e.g., Tideglusib (4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione), or a pharmaceutically acceptable salt or derivative thereof. In other embodiments, the glycogen synthase kinase 3 inhibitor is a maleimide-based glycogen synthase kinase 3 inhibitor, e.g., SB-216763 (3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) or a pharmaceutically acceptable salt or derivative thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: February 28, 2023
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Andrea Gramatica, Warner C. Greene
  • Compositions And Methods For Reactivating Latent Immunodeficiency Virus Using A Gsk-3 Inhibitor
    Publication number: 20200085797
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus using a glycogen synthase kinase 3? inhibitor, such as a glycogen synthase kinase 3? (GSK-3?) or a glycogen synthase kinase 3? (GSK-3?) inhibitor. In some embodiments, the glycogen synthase kinase 3 inhibitor is a glycogen synthase kinase antagonist, e.g., Tideglusib (4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione), or a pharmaceutically acceptable salt or derivative thereof. In other embodiments, the glycogen synthase kinase 3 inhibitor is a maleimide-based glycogen synthase kinase 3 inhibitor, e.g., SB-216763 (3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) or a pharmaceutically acceptable salt or derivative thereof.
    Type: Application
    Filed: June 5, 2018
    Publication date: March 19, 2020
    Inventors: Andrea Gramatica, Warner C. Greene
  • COMPOSITION FOR TREATING CANCER BY THE CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE
    Publication number: 20130266637
    Abstract: The invention relates to a novel composition for treating cancer, which allows the active substance to be released in the direct presence of the cells which are to be treated with the active substance. Said composition comprises an active substance carrier which is in the form of a liposome comprising a disulfide group, a cytostatic agent being contained in the active substance carrier. The invention also relates to a method for the locally defined release of a cytostatic agent.
    Type: Application
    Filed: October 11, 2011
    Publication date: October 10, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Holger Egger, Bastian Budde, Kai Termming, Anna Arbuzova, Andrea Gramatica, Andreas Herrmann, Juergen Liebscher, Nicolai Brodersen